Influence of the Use of Specific Nutritional Formulas on Time in Range in Patients With Type 2 Diabetes
NCT07666581 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 198
Last updated 2026-06-24
Summary
Who can participate?
Individuals may be eligible to join this study if they meet the following criteria:
* Are 18 years or older.
* Have Type 2 diabetes with an A1c level higher than 7%.
* Have a Body Mass Index (BMI) between 27 and 35 (considered overweight or Class 1 obesity).
* Have used a continuous glucose monitor (CGM) successfully in the past.
How the study works:
If eligible individuals decide to join and sign the consent form, a computer will randomly assign them into one of two groups:
The Formula Group: Participants will replace their usual breakfast and one snack with a specific diabetes nutritional drink (Glucerna®).
The Standard Diet Group: Participants will follow a standard low-calorie meal plan without using the nutritional drink.
Both groups will aim for a specific daily calorie goal (1,200-1,500 for women; 1,500-1,800 for men) and will receive expert nutritional counseling.
Monitoring and Follow-up
Over the course of 3 months, close contact will be maintained to support participants:
Every 2 weeks: A nutrition expert will call participants to check on their diet and help with their glucose monitor.
Every month: Participants will meet with the study team in person to review glucose monitor data.
Tests: At the start and end of the study, weight, body composition, blood sugar (A1c), and cholesterol levels will be measured to see how the plans worked.
Conditions
- Type 2 Diabetes
- Obesity & Overweight
- Time in Range
Interventions
- DIETARY_SUPPLEMENT
-
Glucerna
A calorie-restricted diet plan is prescribed (see Table 1). In this group, Glucerna will be prescribed for breakfast and snacks as part of the total calories calculated for each patient's meal plan. Dietary plan prescription of 1200 to 1500 kcal for women and 1500 to 1800 kcal for men.
- OTHER
-
Caloric restriction
Dietary plan prescription of 1200 to 1500 kcal for women and 1500 to 1800 kcal for men.
Sponsors & Collaborators
-
Abbott Nutrition
collaborator INDUSTRY -
Hospital Universitario San Ignacio
lead OTHER
Principal Investigators
-
Ana M Gómez-Medina, Endocrinologyst · Hospital Universitario San Ignacio
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-08-31
- Primary Completion
- 2028-04-30
- Completion
- 2028-12-31
Countries
- Colombia
More Related Trials
-
Continuous Glucose Monitoring (CGM) in an Underserved Population
NCT07135531 ·Status: RECRUITING ·Phase: NA
-
Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food
NCT00818077 ·Status: COMPLETED
-
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
NCT02073058 ·Status: COMPLETED
-
Continuous Glucose Monitoring (CGM) With a Low Carbohydrate Diet to Reduce Weight in Patients With Pre-Diabetes
NCT03695913 ·Status: COMPLETED ·Phase: NA
-
Efficacy of the Use of Real-time Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes and Stage 3 and 4 Chronic Kidney Disease.
NCT07668219 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes
NCT02082184 ·Status: COMPLETED ·Phase: NA
-
Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes
NCT01237301 ·Status: COMPLETED ·Phase: NA
-
A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes
NCT02258373 ·Status: COMPLETED ·Phase: NA
-
Feasibility of a Diabetes Self-Management Program With Continuous Glucose Monitoring for Adults With Type 2 Diabetes
NCT07743307 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effect on HbA1c of the Initiation of CGM in Adults With Type 2 Diabetes Treated With Basal Insulin in Finland
NCT06268821 ·Status: TERMINATED ·Phase: NA
-
T2D Intermittent Nonprescription Sensors for Informed Glucose Health Tracking
NCT07422831 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
NCT03620357 ·Status: COMPLETED ·Phase: NA
-
DIabetes GLycemic Assessment in Newly Confirmed Episodes
NCT07690163 ·Status: RECRUITING ·Phase: NA
-
Effect of Switching From Intermittently Scanned to Real-time Continuous Glucose Monitoring on Diabetes Management in Adults With Type 2 Diabetes (Switch CGM T2D)
NCT06805786 ·Status: RECRUITING
-
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
NCT03730480 ·Status: COMPLETED ·Phase: NA
-
PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm
NCT03251079 ·Status: COMPLETED ·Phase: NA
-
Continuous Glucose Monitoring in Metabolic Surgery
NCT07095972 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
My Diabetes Study - CGM Initiation Approach & Time In Range
NCT05928572 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People With T2 Diabetes
NCT04843527 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Effectiveness of Glunovo Real-Time Continuous Glucose Monitoring in Adults With Type 2 Diabetes
NCT07089979 ·Status: COMPLETED ·Phase: NA
-
FreeStyle Libre 2 Discharge Trial
NCT05822232 ·Status: UNKNOWN ·Phase: NA
-
Tolerability, Acceptance, and Utility of Intermittent CGM Use in Youth With Prediabetes
NCT05505565 ·Status: COMPLETED ·Phase: NA
-
Steno2tech - Continuous Glucose Monitoring and Type 2 Diabetes.
NCT04331444 ·Status: COMPLETED ·Phase: NA
-
CGM Use in Adults With Type 2 Diabetes on Basal Insulin
NCT05944432 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Time in Glucose Hospital Target
NCT05135676 ·Status: COMPLETED ·Phase: NA